Re: Ranibizumab monotherapy versus single-session verteporfin photodynamic therapy combined with as-needed ranibizumab treatment for the management of neovascular age-related macular degeneration.

摘要

"We read with great interest the study by Bashshur et al. The results of this study are not comparable with other studies such as MONT BLANC and DENALI trial, which were double-masked, randomized, clinical trials, in which the visual gain in combination therapy group was not inferior to mono-therapy group.2'3 The probable reason for the poorer visual outcome in the combination therapy group of the present study could be the bias toward the undertreatment in this group. This outcome could have been avoided by masking the examiner to the treatment groups.The authors have also stated that combination therapy is better for patients with macular edema resistant to ranibizumab monotherapy, but this is not conclusively proven in the study.